Key Highlights

  • Net loss for the third quarter was USD 26.8 million, compared with USD 22.2 million a year earlier, as the operating loss widened 34% to USD 29.8 million. Nine-month net loss was USD 78.5 million.
  • Research and development expense rose 27% to USD 21.3 million, and selling, general and administrative expense jumped 55% to USD 8.9 million in the quarter.
  • Cash, cash equivalents and restricted cash were USD 236.3 million at September 30, 2026, and the company said it expects that to cover operating needs for at least twelve months.
  • Net sales were USD 519 thousand, up 21% from USD 429 thousand, on tissue product sales to 4C Medical Technologies, as the Supply agreement with that customer expired June 1, 2026.

Wider Third-Quarter Loss on Trial and Manufacturing Spend

Anteris Technologies Global (NASDAQ:AVR) filed its Quarterly Report on November 10, 2026 for the quarter ended September 30, 2026. The net loss of USD 26.8 million compared with USD 22.2 million a year earlier, while the nine-month loss was USD 78.5 million against USD 65.2 million. Operating expenses rose on R&D tied to scaling manufacturing, preparing for commercialization and running the global pivotal trial, plus higher headcount. Other non-operating income, net, was USD 2.6 million in the quarter against USD 0.1 million, which softened the loss. The filing gives no per-share loss in the extract. Gross Margin on tissue sales was described as consistent with the prior year.

PARADIGM Trial Expands Across Countries

Anteris is a development-stage cardiac care company building the DurAVR transcatheter heart valve for aortic stenosis, a narrowing of the aortic valve. The PARADIGM trial randomizes patients between DurAVR and an approved valve, with a one-year primary endpoint of death, stroke and cardiovascular hospitalization. Recruitment began in Europe in October 2025, and first United States patients were treated in May 2026. After quarter end the trial won clearance in Germany and approval in Australia. The company said the trial could supply the evidence for a premarket approval decision by the FDA, though no approval timing was given. The filing cites early clinical experience in over 130 patients treated with the valve.

Cash Pile, Equity Raises and the Revenue Question

Revenue is tiny next to spending, with nine-month net sales of USD 2.0 million against an operating loss of USD 84.8 million. Funding came mainly from a January 2026 offering and a Medtronic private placement, which together raised about USD 320.0 million gross, and a USD 250.0 million at-the-market program set up in May had sold no shares by September 30. Nine-month operating cash outflow was USD 72.4 million versus USD 59.3 million. The company said it still needs additional funds to reach its long-term goals, and an equity raise would dilute holders. The company also took occupancy of a Minnesota manufacturing Facility on September 1, 2026.

Where Things Stand

The loss widened because the company is spending ahead of any product revenue. Anteris Technologies Global (NASDAQ:AVR) lost USD 26.8 million in the quarter as R&D and administrative costs grew faster than tiny sales of USD 519 thousand, partly offset by USD 2.6 million of other income. The Balance Sheet is the buffer, with USD 236.3 million of cash and a stated twelve-month runway. Items to watch are PARADIGM enrollment, new country activations, quarterly cash burn and whether the unused at-the-market program is drawn.